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Many clinically important tissues are refractory to adenovirus (Ad) infection due to negligible levels of the primary Ad5 receptor the coxsackie
and adenovirus receptor CAR. Thus, development of novel CAR-independent Ad vectors should lead to therapeutic gain. Ovine atadenovirus type
7, the prototype member of genus Atadenovirus, efficiently transduces CAR-deficient human cells in vitro, and systemic administration of OAdV
is not associated with liver sequestration in mice. The penton base of OAdV7 does not contain an RGD motif, implicating the long-shafted fiber
molecule as a major structural dictate of OAdV tropism. We hypothesized that replacement of the Ad5 fiber with the OAdV7 fiber would result in
an Ad5 vector with CAR-independent tropism in vitro and liver “detargeting” in vivo. An Ad5 vector displaying the OAdV7 fiber was constructed
(Ad5Luc1-OvF) and displayed CAR-independent, enhanced transduction of CAR-deficient human cells. When administered systemically to
C57BL/6 mice, Ad5Luc1-OvF reporter gene expression was reduced by 80% in the liver compared to Ad5 and exhibited 50-fold higher gene
expression in the kidney than the control vector. To our knowledge, this is the first report of a fiber-pseudotyped Ad vector that simultaneously
displays decreased liver uptake and a distinct organ tropism in vivo. This vector may have future utility in murine models of renal disease.
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Vectors based on human adenovirus (Ad) serotypes 2 and 5
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doi:10.1016/j.virol.2006.01.037attributes: Ad vectors display in vivo stability and excellent
gene transfer efficiency to numerous dividing and non-dividing
cell targets. In addition, Ad vectors are rarely linked to any
severe disease in immunocompetent humans, providing ratio-
nale for further development of these vehicles.
The first step in Ad5 infection occurs via high-affinity
binding of the virion fiber knob domain to its cognate cellular
receptor known as the coxsackie and adenovirus receptor
(CAR) (Henry et al., 1994; Xia et al., 1994; Bergelson et al.,
1997; Tomko et al., 1997). Following knob-CAR binding,
receptor-mediated endocytosis of the virion is dramatically
increased by interaction of the penton base Arg–Gly–Asp
(RGD) motif with cellular integrins αvβ3, αvβ5, αvβ1, α3β1
or other integrins (Bai et al., 1993; Wickham et al., 1993; Louis
Fig. 1. Diagram depicting the design of the chimeric fiber and molecular validation of Ad5Luc1-OvF. (A) Construction of the 553-amino-acid chimeric fiber of
Ad5Luc1-OvF, including the N-terminal amino acid sequences of the OAdV7 and human Ad5 fiber proteins. The LSL sequence common to both fibers that served as
the junction for the replacement of the OAdV7 tail domain, as well as other common sequences, is highlighted. The final Ad5Luc1-OvF fiber sequence is underlined,
and the arrow highlights that Val46 of the Ad5 tail domain is followed by Leu37 in the OAdV7 fiber. (B) PCR analysis of fiber genes using Ad genomes from rescued
viral particles as the PCR templates. Ad5Luc1 virions and fiber shuttle plasmid pNEB.PK3.6-OvF (designated as pNEB-OvF in the figure) were used as controls.
Lanes containing DNA size standards (M) and no PCR template (NT) are designated. Primers used are specific for the OAdV7 or Ad5 fiber gene knob domain. PCR
products indicating the presence of the Ad5 or OAdV7 fiber knob domains are 540 and 366 bp, respectively. (C) Western blot analysis of fiber proteins from purified
virions. 1 × 1010 vp of Ad5Luc1 with wild-type Ad5 fiber (lanes 3,4) or Ad5Luc1-OvF with chimeric OAdV7 fiber (lanes 1, 2) were resuspended in Laemmli buffer
prior to SDS-PAGE andWestern analysis with an anti-tail Ad5 fiber mAb. Samples in lanes 1 and 3 were heated to 99 °C prior to electrophoresis. Fiber monomers (M)
and trimers (T) are indicated. Molecular mass markers indicate kilodaltons.
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2003).
Understanding of this two-step Ad entry pathway explains
clinical findings by several groups that have demonstrated that
cells expressing low levels of CAR are refractory to Ad
infection and gene delivery. Native CAR-dependent tropism
results in a scenario wherein non-target but high-CAR cells can
be infected while target tissues, if low in CAR, are resistant to
Ad infection. Essentially, while Ad delivery is uniquely efficient
in vivo, the biodistribution of CAR is incompatible with many
gene therapy interventions and in vivo co-localization of
applied Ad vectors and the receptor is poor (Dmitriev et al.,
1998; Miller et al., 1998; Fechner et al., 1999; Li et al., 1999;
Cripe et al., 2001).
Based on a clear understanding of native Ad cell recognition,
the development of CAR-independent Ad vectors has rationally
focused on the fiber protein, the primary determinant of Ad
tropism. Ad fiber pseudotyping, the genetic replacement of the
knob domain or entire fiber with its structural counterpart from
another human Ad serotype, has been employed as a means to
derive Ad5-based vectors with CAR-independent tropism by
virtue of the natural diversity in receptor recognition found in
species B and D Ad fibers (Büchen-Osmond, 2002) and has
identified chimeric vectors with superior infectivity to Ad5 in a
variety of clinically relevant cell types (Gall et al., 1996;
Shayakhmetov et al., 2000; Von Seggern et al., 2000; Chiu et
al., 2001; Goossens et al., 2001; Havenga et al., 2001;
Jakubczak et al., 2001; Havenga et al., 2002; Kanerva et al.,
2002).
The development of non-human adenoviruses as gene
therapy vehicles has been proposed (Khatri et al., 1997;
Rasmussen et al., 1999; Reddy et al., 1999a, 1999b; Kremer
et al., 2000; Loser et al., 2002; Hemminki et al., 2003). The
rationale for these efforts has been three-fold: (1) no pre-
existing humoral or cellular immunity will exist against “xeno”
Ads in the majority of humans (Hofmann et al., 1999; Kremer et
al., 2000), (2) several non-human Ads have been demonstrated
to efficiently infect human cells without subsequent replication,
including canine, bovine and murine mastadenoviruses (Gelhe
and Smith, 1969; Nguyen et al., 1999; Rasmussen et al., 1999;
Soudais et al., 2000) and ovine atadenovirus (Loser et al., 2000;
Kumin et al., 2002) and (3) novel entry biologies of xeno Ads
may circumvent CAR deficiency in clinically relevant human
target tissues refractory to Ad5-based vectors.
Consistent with these considerations, the 287 isolate of the
ovine adenovirus type 7 (OAdV7) has been evaluated as a
potential human gene therapy vector (Voeks et al., 2002; Loser
et al., 2003; Martiniello-Wilks et al., 2004; Wang et al., 2004).
OAdV7 is the prototype isolate of a novel genus of viruses
referred to as atadenovirus (Benko and Harrach, 1998). OAdV7
causes only mild symptoms in sheep and infects numerous
human cell types efficiently, although replication in human cells
is abortive due to the lack of viral promoter function (Boyle et
al., 1994; Khatri et al., 1997; Rothel et al., 1997). OAdV7
displays CAR-independent tropism that is distinct from that of
serotype 2 and 5 Ads, utilizing an unknown primary receptor(s)
(Xu and Both, 1998). In addition, systemically applied OAdV7exhibits a distinctive tissue distribution in vivo that is less
hepatotropic in mice compared to Ad5-based vectors (Hofmann
et al., 1999).
OAdV7 tropism is mediated via a 543-residue fiber molecule
comprised of a 35 residue N-terminal tail region, a long shaft
domain predicted to consist of 25 pseudorepeats and a relatively
small 121-amino-acid C-terminal region comprising the knob
domain (Vrati et al., 1995). In contrast to Ad5, the OAdV7 fiber
does not contain the lysine-rich KKTK sequence found in the
third repeat of the Ad5 fiber, a motif suggested to mediate
hepatotropism of Ad5 vectors in rodents and primates in vivo
(Smith et al., 2003a, 2003b). In addition, neither the penton
nor fiber of OAdV7 contains an RGD sequence or other iden-
tifiable integrin-binding domain, suggesting that interaction
with cell-surface integrins may not be required for infection
(Vrati et al., 1996; Xu and Both, 1998). Thus, the fiber protein is
the only structural determinant of OAdV7 tropism identified to
date.
Based on the unique tropism of OAdV7 that combines CAR
independence with a non-hepatotropic biodistribution profile,
we hypothesized that an Ad5 vector, containing the OAdV7
fiber as well as its native penton base RGD, would achieve
enhanced infectivity of Ad-refractory cell types in vitro and
liver detargeted tropism in vivo.
Results
Generation of modified Ad5 containing the OAdV7 fiber
The OAdV7 fiber molecule is composed of homotrimers of a
543-amino-acid polypeptide. Predicted functional domains
within the fiber are the tail domain spanning residues 1 to 35,
the shaft domain from 36 to 422 containing approximately 25
pseudorepeats motifs and the 121-amino-acid fiber knob
domain from 423 to 543 (Vrati et al., 1995). Most mammalian
Ads contain a conserved threonine–leucine–tryptophan–threo-
nine (TLWT) motif at the N-terminus of the fiber knob domain,
and in human Ad2 and Ad5, a flexible region separating the
shaft and the knob domains precedes this motif (van Raaij et al.,
1999). The OAdV7 fiber does not contain this motif, thus the
start of the knob domain is poorly defined.
Following examination of Ad5 and OAdV7 fiber polypep-
tide sequences, we identified a common leucine–serine–leucine
(LSL) sequence common to both fibers immediately down-
stream of each tail domain (Fig. 1A). The LSL region was
considered a common element in both fibers; therefore, we
substituted the 44-amino-acid Ad5 tail domain for the native
OAdV7 tail domain upstream of the LSL sequence to provide
the correct penton base insertion domain for incorporation into
the Ad5 capsid. This was accomplished using a two-plasmid
rescue system essentially as described (Krasnykh et al., 1996;
Glasgow et al., 2004). We constructed an E1-deleted recombi-
nant Ad genome (Ad5Luc1-OvF) containing the chimeric Ad5
tail/OAdV7 fiber gene and a firefly luciferase reporter gene
controlled by the CMV immediate early promoter/enhancer in
the E1 region. Genomic clones of Ad5Luc1-OvF were
sequenced, and two correct clones were chosen. Ad5Luc1-
Table 1
Ad5Luc1-OvF luciferase gene expression in various cancer cell lines
Cell line Origin CARa Fold increase
in luciferase
activity vs.
Ad5 b
Reference
CHO Hamster ovary L/N 22 Soudais et al.,
2000
RD Rhabdomyosarcoma L/N 1.5 Dmitriev et
al., 1998;
Cripe et al.,
2001
PC-3 Prostate cancer L/N 7.8 Okegawa
et al., 2000
LNCaP Prostate cancer M 5% of Ad5 Okegawa
et al., 2000
T24 Bladder cancer L/N 9.8 Li et al., 1999
MCF7 Breast cancer L/N 9.2 Y. Kawakami,
unpublished
data
HeLa Cervical cancer H 13% of Ad5 Bergelson
et al., 1997
LoVo Colon cancer ND 60% of Ad5
oLE Ovine normal
stroma
ND 2.7
JS8JSRV Ovine lung cancer ND 5% of Ad5
U118MG Glioma L/N 2.2 Kim et al.,
2003
U118
CAR-
tailless
Glioma H 1% of Ad5 Kim et al.,
2003
OV-3 Ovarian cancer ND 23
OV-4 Ovarian cancer L/N 3.0 Hemminki
et al., 2003
HEY Ovarian cancer L/N 6.5 Hemminki
et al., 2003
SKOV Ovarian cancer ND 1
S KOV 3 .
ip1
Ovarian cancer L/N 5.0 Hemminki
et al., 2003
FaDu Pharynx cancer L/N 21% of Ad5 Blackwell
et al., 1999
SCC-4 Tongue cancer L/N 9.7 Blackwell
et al., 1999
SCC-25 Tongue cancer M 9% of Ad5 Blackwell
et al., 1999
THLE-3 Normal liver
epithelial
ND 10% of Ad5
Primary Cells
Patient 1 Ovarian cancer ND 4
a H, high levels of CAR; M, moderate; L/N, little or no CAR; ND, not
determined. As determined by FACS analysis.
b 100 vp/cell, luciferase activity measured at 24 h post-infection.
Fig. 2. Ad5Luc1-OvF-mediated gene transfer. Luciferase activities following
transduction of a panel of CAR-deficient cell lines (A) and precision-cut human
ovarian cancer tissue slices (B). Luciferase activity was determined 24 h post-
transduction and is reported in relative light units (RLU) in panel A and RLU/mg
cellular protein in panel B. Each column is average of 4 replicates using 100 vp/
cell, and the error bar indicates the standard deviation.
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Ad5Luc1-OvF were purified by double CsCl gradient centri-
fugation. The concentration of Ad5Luc1-OvF was 2.7 × 1012
viral particles (vp)/ml, while the control vector Ad5Luc1 was
3.74 × 1012 vp/ml. Ad5Luc1 contains the wild-type Ad5 fiber
and is isogenic to Ad5Luc1-OvF in all respects except for the
fiber shaft and knob domains.
We confirmed the fiber knob genotype of Ad5Luc1-OvF via
diagnostic PCR, using knob-domain-specific primer pairs and
genomes from purified virions as PCR templates. Plasmidscontaining the fiber sequence of the wild-type OAdV7 fiber
(data not shown) or the chimeric fiber gene were used as
positive controls (Fig. 1B). To further confirm that Ad5Luc1-
OvF virions contained trimeric fibers, we performed SDS-
PAGE followed by Western blot analysis of vector particles. We
used the monoclonal 4D2 primary antibody that recognizes the
Ad5 fiber tail domain common to both the Ad5 and chimeric
OAdV7 fiber molecules. We observed bands at approximately
185 kDa for Ad5Luc1-OvF and control Ad5Luc1 virions,
corresponding to trimeric fiber molecules. Bands of boiled
samples resolved at an apparent molecular mass of approxi-
mately 60–65 kDa, indicative of fiber monomers (Fig. 1C).
Ad5Luc1-OvF vector exhibits expanded tropism and enhanced
gene transfer
We hypothesized that the incorporation of the OAdV7
fiber into the Ad5 capsid would provide augmented
Fig. 3. FACS analysis of Ad5Luc1 and Ad5Luc1-OvF binding to U118-hCAR-
tailless (upper panel) or CHO cells (lower panel). Aliquots of 2 × 105 cells were
incubated with polyclonal rabbit anti-Ad5 antiserum following binding of virus
to the cells at 4 °C (to block internalization). Cells were incubated in the
presence of anti-rabbit FITC-labeled secondary antibody and subjected to flow
cytometry analysis. The gray peaks in the histograms represent negative control
cells incubated with primary and secondary antibodies only. The thin line
indicates Ad5 cellular attachment, and the heavy line indicates Ad5Luc1-OvF
attachment. In U118-hCAR-tailless cells, approximately 94% of cells were
positive for Ad5Luc1 surface attachment (thin line), while only 8% of cells
were positive for Ad5Luc1-OvF (heavy line) versus control cells receiving
primary and secondary antibodies (gray peak). In CHO cells, 10% of cells were
positive for Ad5Luc1 attachment compared to 60% of positive cells for
Ad5Luc1-OvF.
Fig. 4. Ad5Luc1 and Ad5Luc1-OvF-mediated gene transfer with Ad5 knob
blocking. Luciferase activities following transduction of low-CAR U118MG
cells and CAR-expressing U118-hCAR-tailless cells (A), transduction of U118-
hCAR-tailless with Ad5Luc1 (white squares) or Ad5Luc1-OvF (black squares)
with Ad5 knob block (B) and low-CAR SKOV3.ip1 cells with Ad5 knob block
(C). Concentration of recombinant Ad5 fiber knob protein used to block
transduction is indicated in μg/ml. Luciferase activity was determined 24 h post-
transduction and is reported in relative light units (RLU) (A) or in percent total
of unblocked luciferase activity for ease of comparison (B,C). Each column is
average of 4 replicates using 100 vp/cell, and error bar indicates standard
deviation.
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CAR-independent tropism. We therefore evaluated Ad5Luc1-
OvF transduction of a panel of cell lines expressing variable
levels of CAR (Table 1). As shown in Fig. 2A, Ad5Luc1-OvF
provided augmented reporter gene delivery to several CAR-
deficient cell lines, with augmentation up to 23-fold compared to
Ad5Luc1. Furthermore, Ad5Luc1-OvF increased gene transfer
to an unpassaged primary ovarian cancer patient sample as much
as 5-fold versus Ad5Luc1 (Fig. 2B). Of interest, Ad5Luc1-OvF
gene delivery augmentation to CAR-deficient RD cells (human
rhabdomyosarcoma, 1.5-fold) was markedly lower than that of
OV-3 cells (human ovarian cancer, 23-fold) and CAR-deficient
CHO cells (Chinese hamster ovary, 22-fold), suggesting that RD
cells do not express the requisite cell-surface molecule(s) for
OAdV7 fiber recognition. We also evaluated Ad5Luc1-OvF
transduction on a normal human liver epithelial cell line (THLE-3) and observed a 10-fold reduction in gene transfer compared to
Ad5Luc1.
Ad5Luc1-OvF exhibits increased cell-surface binding in the
absence of CAR
To investigate whether Ad5Luc1-OvF mediates increased
gene transfer via enhanced cell-surface interaction and not
altered intracellular trafficking, we performed cell-binding
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virions. We hypothesized that Ad5Luc1-OvF would display
increased attachment to CAR-deficient cells, and possibly even
CAR-positive cells, compared to Ad5 by virtue of novel virion/
cell interaction. For these studies, we selected cell lines that
exhibited maximally different gene transfer profiles between
Ad5Luc1 and Ad5Luc1-OvF: CAR-deficient CHO cells and the
CAR-positive U118-hCAR-tailless cell line that artificially
expresses the extracellular domain of human CAR (Kim et al.,
2002). Cells were incubated with Ad vectors at 4 °C to allow
virion attachment, but not internalization, followed by labeling
of bound virions with an anti-Ad primary antibody and an
FITC-conjugated secondary antibody, with subsequent FACS
analysis (see Materials and methods). As shown in Fig. 3A,
surface-bound Ad5Luc1 was detected on 94% of U118-hCAR-
tailless cells, while only 8% of these cells were positive for
Ad5Luc1-OvF. This observation is consistent with the 100-fold
disparity in gene transfer observed for these vectors in the same
cell line (Table 1, Fig. 4A). In contrast, only 10% of CAR-
negative CHO cells bound Ad5Luc1, while over 60% of CHO
cells were positive for Ad5Luc1-OvF (Fig. 3B). These data
indicate that a direct positive correlation exists between
increased Ad5Luc1-OvF cell-surface interaction and enhanced
gene delivery in CAR-deficient cells.
The OAdV7 fiber in Ad5Luc1-OvF dictates CAR-independent
tropism
As shown in Table 1 and Fig. 3, Ad5Luc1-OvF gene transfer
and cell binding were not dependent on the presence of CAR.
To confirm this aspect of Ad5Luc1-OvF tropism, we performed
knob-blocking assays using recombinant Ad5 fiber knobFig. 5. In vivo biodistribution of Ad5-based vectors after intravenous injection into f
Ad5Luc1 (open bars), Ad5Luc1-OvF (black bars) or Ad5-ΔdKKTK (cross-hatched
individual experiments using different preparations of Ad5Luc1-OvF were combin
concentration for each individual organ. Each data point is an average of 8–10 mice
indicate standard deviation. *P b 0.0028 versus Ad5Luc1 in liver, #P b 0.042 versus
were significantly lower than Ad5Luc1, P b 0.017. In all cases, a two-tailed t test aprotein, a well-established method for demonstrating or ruling
out CAR-mediated infection (Krasnykh et al., 1998; Einfeld et
al., 2001; Glasgow et al., 2004). As shown in Fig. 4A, Ad5Luc1
exhibited clear CAR-dependent tropism as demonstrated by a
100-fold increase in transgene expression in U118-hCAR-
tailless cells versus the CAR-deficient U118MG cell line.
Furthermore, preincubation of cells with recombinant Ad5 knob
protein at 50 μg/ml inhibited 90% and 50% of Ad5 Luc1 gene
transfer to U118-hCAR-tailless cells and low-CAR SKOV3.ip1
cells, respectively (Figs. 4B, C). Conversely, Ad5Luc1-OvF
gene delivery to U118MG cells was 2-fold higher than that of
Ad5Luc1, and transduction of the highly CAR-positive variant
line yielded no increase in luciferase values. Furthermore,
competitive inhibition with Ad5 knob did not appreciably block
Ad5Luc1-OvF-mediated gene transfer in either cell line,
confirming the CAR-independent tropism of this vector.
Biodistribution of Ad5Luc1-OvF gene expression in mice
Following confirmation of our first hypothesis that the
Ad5Luc1-OvF vector would exhibit enhanced infectivity in low
CAR substrates via a novel, non-CAR based tropism, we next
addressed the biodistribution profile of Ad5Luc1-OvF. Based
on the biodistribution of intravenously applied OAdV7 in mice
(Hofmann et al., 1999) and the lack of the putative heparin
sulfate binding motif KKTK in the OAdV7 fiber shaft, we
hypothesized that an Ad5 vector containing this fiber would
demonstrate decreased hepatotropism in vivo. To this end, we
evaluated the biodistribution of transgene expression of a panel
of Ad vectors including Ad5Luc1-OvF, Ad5Luc1 and our
Ad5Luc1-ΔKKTK vector (with the native KKTK sequence
deleted from the fiber shaft) as a liver detargeted control vector,emale C57BL/6 mice. Mice 6–8 weeks of age were injected with 1 × 1011 vp of
bars). Luciferase activity was determined 48 h post-injection. Results from two
ed and are presented as relative light units (RLU) normalized for total protein
(Ad5Luc1, n = 10; Ad5Luc1-OvF, n = 8; Ad5-ΔKKTK, n = 10), and error bars
Ad5Luc1 in kidney. For all tissues except heart, Ad5ΔKKTK luciferase values
ssuming unequal variance between groups was used for increased stringency.
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injected via the tail vein with 1 × 1011 viral particles. Forty-eight
hours post-injection, the liver, spleen, lung, heart and kidney
were harvested and homogenized, and luciferase activity and
protein concentrations of cleared homogenates were measured.
As expected, Ad5Luc1 produced the highest transgene
expression in the liver, while Ad5-ΔKKTK vector gene
expression in liver was reduced to 1% of control (Fig. 5). In
all other organs examined, Ad5-ΔKKTK gene expression was
markedly reduced to less than 7% of Ad5Luc1 control levels.
Ad5Luc1-OvF gene expression was more evenly distributed
among the major organs and was significantly decreased in the
liver to approximately 18% of Ad5Luc1 levels (P b 0.0028).
Ad5Luc1-OvF gene expression in the heart, spleen and lung
was not significantly different from Ad5Luc1. Ad5Luc1-OvF
gene expression in the kidney was increased 50-fold versus the
Ad5Luc1 control vector (P b 0.042), resulting in a liver-to-
kidney gene expression ratio of 0.59 for Ad5Luc1-OvF and
0.002 for Ad5Luc1, a difference of 280-fold. Of note, we
observed a vector-specific difference in animal survival during
the biodistribution studies. In this regard, all animals receiving
control Ad survived the duration of the experiment; however, 3
of 11 mice receiving Ad5Luc1-OvF expired before the 48
h time point. Further analysis of this phenomenon is under
investigation. In the aggregate, Ad5Luc1-OvF, a vector
containing fibers from OAdV7 that are unable to bind CAR,
demonstrates enhanced gene delivery to CAR-deficient human
cells in vitro and displays a unique biodistribution character-
ized by attenuated liver transduction with significant kidney
tropism.
Discussion
Despite a variety of avenues explored to improve human
adenovirus serotype 5 as a therapeutic agent, this vector exhibits
innate drawbacks of CAR dependency and hepatotropism. Of
particular concern is that many clinically important tissues,
including several cancer types, are refractory to Ad5 infection
due to low CAR expression. Indeed, down-regulation of CAR
has been reported for several tumor types, including glioma,
ovarian, lung, breast and others (Miller et al., 1998; Hemminki
and Alvarez, 2002; Bauerschmitz et al., 2002). As a
consequence of limiting CAR levels in many clinically relevant
target cells, high Ad vector dosage is often required for in vivo
efficacy. Given that over 95% of systemically administered Ad
particles are sequestered in the liver via hepatic macrophage
(Kupffer cell) uptake (Tao et al., 2001) and hepatocyte
transduction (Connelly, 1999) of both rodents and primates,
therapeutically relevant Ad doses often result in vector-related
liver toxicity (Peeters et al., 1996; Lieber et al., 1997; Sullivan et
al., 1997; Worgall et al., 1997; Alemany et al., 2000;
Shayakhmetov et al., 2004). Thus, Ad vectors exhibiting
CAR-independent and/or expanded tropism coupled with low
hepatotropism should prove valuable for maximal transduction
of low-CAR targets at the lowest possible vector dose.
We sought to achieve this vector design mandate by
replacing the Ad5 fiber with the corresponding structure fromovine atadenovirus serotype 7. The fiber of OAdV7 is the only
identified structural determinant of native OAdV7 tropism,
which is CAR-independent in vitro and non-hepatotropic when
applied systemically. Genetic incorporation of the OAdV7 fiber
molecule into the Ad5 virion ablated its CAR dependence as
evidenced by competitive Ad5 knob blocking assays as well as
increased cellular attachment to CAR-deficient CHO cells. Our
results are consistent with previous findings showing that Ad5
and OAdV7 do not compete with each other for cell entry in
cells that both viruses can infect (Xu and Both, 1998).
Ad5Luc1-OvF exhibited enhanced infectivity in vitro, provid-
ing 3- to 23-fold increased gene transfer to several CAR-
deficient cell lines and primary ovarian cancer tissue versus
Ad5. However, Ad5Luc1-OvF gene transfer to other CAR-
deficient human cancer cell lines such as SCC-25, FaDu and
LNCaP, as well as the human THLE-3 normal liver cell line,
was markedly reduced compared to the Ad5Luc1 control vector.
These findings suggest that the receptor(s) for the OAdV7 fiber
is not ubiquitously expressed, a biological phenomenon that
may provide the basis of a level of cell- or tissue-type selectivity
of potential utility.
Intravenous administration of Ad results in accumulation in
the liver, spleen, heart, lung and kidneys of mice, although these
tissues may not necessarily be the highest in CAR expression
(Fechner et al., 1999; Reynolds et al., 1999; Wood et al., 1999).
Instead, anatomic barriers, the structure of the vasculature and
the degree of blood flow and in each organ probably contribute
to the biodistribution, in addition to non-specific viral particle
uptake by macrophages. This is true with regard to the liver in
particular, which sequesters the majority of systemically
administered Ad particles via hepatic macrophage (Kupffer
cell) uptake (Tao et al., 2001) and hepatocyte transduction
(Connelly, 1999), leading to cytokine release, inflammation
and liver toxicity (Peeters et al., 1996; Lieber et al., 1997;
Worgall et al., 1997; Shayakhmetov et al., 2004, 2005b).
Thus, the nature of adenovirus–host interactions dictating the
fate of systemically applied Ad has come under considerable
scrutiny.
To this end, attempts to design Ad5 vectors that “detarget”
the liver have been based on the assumption that CAR- and
integrin-based interactions are required for liver uptake in vivo.
The majority of attempts to inhibit hepatocyte and/or liver
Kupffer cell uptake using Ad5 vectors with ablated CAR- or
integrin-binding motifs in the Ad capsid have failed (Alemany
and Curiel, 2001; Mizuguchi et al., 2002; Smith et al., 2002;
Martin et al., 2003; Smith et al., 2003a), although some
mutations of the Ad5 fiber knob have attenuated liver tropism of
vectors following systemic administration (Einfeld et al., 2001;
Koizumi et al., 2003; Yun et al., 2005). Indeed, recent studies
focused on Ad vector biodistribution have demonstrated that
Kupffer cell and hepatocyte uptake in vivo are largely CAR-
independent (Liu et al., 2003; Shayakhmetov et al., 2004),
confirming that native Ad5 tropism determinants at work in
vitro contribute little to vector biodistribution in vivo.
The Ad fiber is a major structural determinant of liver
tropism in vivo, even in the absence of knob/Ad receptor
interaction (Nicklin et al., 2005). In this regard, Smith and co-
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proteoglycan (HSPG)-binding motif, KKTK, in the third repeat
of the native fiber shaft. Replacement of this motif with an
irrelevant GAGA peptide sequence reduced reporter gene
expression and Ad DNA in the liver by 90% in mice and
non-human primates (Smith et al., 2003a). The authors
postulated that removal of the KKTK inhibited Ad5 interaction
with heparin sulfate proteoglycans (HSPG) in the liver;
however, direct binding of this motif to HSPG has not been
demonstrated.
Pseudotyping Ad5 with short-shafted fibers from Ad3, Ad35
or Ad40 that contain no native KKTK results in significant
reduction of liver uptake (Table 2) (Nakamura et al., 2003;
Sakurai et al., 2003; Vigne et al., 2003). Furthermore, the use of
a shortened Ad5 fiber shaft that retains the native KKTK motif
(Vigne et al., 2003) or replacement of the Ad5 shaft with the
short Ad3 shaft domain (Breidenbach et al., 2004) was shown to
attenuate liver uptake in vivo following intravenous delivery.
Indeed, Shayakhmetov and co-workers have recently shown
that short-shafted Ad vectors with either CAR- or non-CAR-
interacting knob domains do not efficiently interact with
hepatocytes in vivo and are not taken up by Kupffer cells
(Shayakhmetov et al., 2004).Table 2
Fiber composition of Ad vectors displaying decreased liver localization in vivo
Ad Vector Tail Shaft Knob Liver deta
Ad5Luc1 Ad5 Ad5 (22 repeats w/KKTK) Ad5 No
Ad5Luc1-OvF Ad5 OAdV7 (25 repeats,
no KKTK)
OAdV7 20% of A
Ad5.Ad3.SH Ad5 Ad3 (6 repeats, no KKTK) Ad5 10% of A
Ad5.Ad3.SH/
knob3
Ad5 Ad3 (6 repeats, no KKTK) Ad3 No
Ad5 DB6 Ad5 Ad3 (6 repeats, no KKTK) Ad3 10% of A
Ad5 BS1 Ad5 Ad5 (9 repeats, w/KKTK) Ad5 10% of A
Ad5.35F Ad35 Ad35 (6 repeats, no KKTK) Ad35 4% of Ad
Ad5.5S35H Ad5 Ad5 Ad35 No
Ad5.35S5H Ad35 Ad35 (6 repeats, no KKTK) Ad5 25% of A
Ad5/35 Ad5 Ad35 (6 repeats, no KKTK) Ad35 No
Ad5.KO1 Ad5 Ad5 CAR-ablated
Ad5
No
Ad5.S Ad5 Ad5 (KKTK to GAGA) Ad5 6% of Ad
Ad5.K01.S Ad5 Ad5 (KKTK to GAGA) CAR-ablated
Ad5
0.001% o
Ad5F35L Ad5 Ad35 (6 repeats, no KKTK) Ad35 0.001% o
Ad5F/40S Ad40 Ad40 (7 repeats, no KKTK) Ad40 1% of Ad
Ad5/35L Ad5 Ad5 (22 repeats, w/KKTK) Ad35 No
Ad5/35S Ad5 Ad35 (6 repeats, no KKTK) Ad35 b10% of A
Ad5/9L Ad5 Ad5 (22 repeats) Ad9 No
Ad5/9S Ad5 Ad9 (7 repeats, no KKTK) Ad9 b10% of AThe Ad5Luc1-OvF fiber contains 25 pseudorepeats, no
KKTK motif and likely forms a fiber at least as long as the
native Ad5 fiber. Long-shafted Ads have been shown to
accumulate within liver sinusoids and subsequently infect
hepatocytes in a CAR-independent manner (Shayakhmetov et
al., 2004). Thus, our result demonstrating marked reduction of
in vivo liver gene expression appears to be unique for a long-
shafted Ad vector and is comparable to results obtained with
some short-shafted Ads (Table 2).
Recent evidence has highlighted the importance of serum
factors in the hepatic uptake of systemically applied Ad vectors.
Shayakhmetov and colleagues demonstrated that coagulation
factor IX (FIX) and complement component C4-binding protein
(C4BP) can direct Ad biodistribution in vivo by cross-linking
Ad to hepatocellular HSGP and the LDL-receptor-related
protein. Kupffer cell sequestration of Ad particles was likewise
dependent on Ad association with FIX and C4BP (Shayakhme-
tov et al., 2005a). This work also demonstrated a key vector
design approach whereby genetic modification of solvent-
exposed loop structures in the Ad5 fiber knob attenuated serum
factor binding resulting in reduced liver uptake in vivo. In
addition to the Ad5Luc1-OvF vector, this serum-factor-ablated
Ad vector is the only other long-shafted liver-detargeted Adrgeting New in vivo
tropism
Dose (vp)/Strain Reference
– 1 × 1011/C57BL/6 This report
d5 Kidney, equal to liver 1 × 1011/C57BL/6 This report
d5 None reported 5 × 1010/C57BL/6 Breidenbach et al.,
2004
None reported 5 × 1010/C57BL/6 Breidenbach et al.,
2004
d5 None reported 1 × 1011/C57BL/6 Vigne et al., 2003
d5 None reported 1 × 1011/C57BL/6 Vigne et al., 2003
5 None reported 2 × 1011/C57BL/6 Smith et al.,
2003a,b
None reported 2 × 1011/C57BL/6 Smith et al.,
2003a,b
d5 None reported 2 × 1011/C57BL/6 Smith et al.,
2003a,b
Kidney, 1% of liver 1 × 1010/C57BL/6 Mizuguchi et al.,
2002
None reported 2 × 1011/C57BL/6 Smith et al.,
2003a,b
5 None reported 2 × 1011/C57BL/6 Smith et al.,
2003a,b
f Ad5 None reported 2 × 1011/C57BL/6 Smith et al.,
2003a,b
f Ad5 None reported 1.5 × 1010/C57BL/6 Sakurai et al., 2003
5 None reported 2 × 1010/C57BL/6 Nakamura et al.,
2003
None reported 1 × 1011/C57BL/6 Shayakhmetov
et al., 2004
d5/35L None reported 1 × 1011/C57BL/6 Shayakhmetov
et al., 2004
None reported 1 × 1011/C57BL/6 Shayakhmetov
et al., 2004
d5/9L None reported 1 × 1011/C57BL/6 Shayakhmetov
et al., 2004
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liver uptake observed with Ad5Luc1-OvF is the result of the
unique structure of the ovine fiber resulting in reduced and/or
altered interaction with blood factors that mediate native Ad5
liver uptake.
Gene transfer to the kidney could have significant utility for
the treatment of renal disease and in transplantation paradigms
(Imai et al., 2004). While Ad, adeno-associated virus (AAV) and
retroviral vectors transduce renal cells in vitro, systemic delivery
of viral vectors has resulted in insufficient gene delivery to the
kidney (Moullier et al., 1994; Takeda et al., 2004; Fujishiro et al.,
2005). To increase in vivo gene transfer to the kidney, perfusion
(Heikkila et al., 1996), catheter infusion (Takeda et al., 2004;
Fujishiro et al., 2005) and direct interstitial injection (Ortiz et al.,
2003) have been employed. Considering the established
difficulty of generating Ad-mediated renal gene transfer via
systemic injection, our result demonstrating abundant kidney
gene expression by Ad5Luc1-OvF is notable. While the
mechanism of enhanced kidney gene expression remains
under investigation, we interpret this result as a consequence
of unique, direct interaction(s) of Ad5Luc1-OvF with kidney
and/or renal vasculature, and not solely as a result of decreased
liver sequestration, since other Ad vectors exhibiting decreased
hepatotropism have not demonstrated appreciable novel tissue
tropism (Table 2).
The kidney is a complex organ with numerous specialized
compartments including the glomeruli, tubules, interstitium and
vasculature. The glomerular capillary endothelium is fenestrat-
ed, resulting in the “leaky” vasculature that would allow
intravenous Ad vectors to contact the underlying filtration
membrane and access to the epithelium of the renal tubule
system. Indeed, injection of an Ad vector directly into the renal
artery can result in gene transfer to cells of the proximal tubule
(Moullier et al., 1994). Given the unique renal localization
observed, we are currently extending our studies to determine
the precise localization of Ad5Luc1-OvF gene expression within
kidney substructures. An important issue related to the renal
localization is the toxicity we observed while carrying out these
studies. Given that only animals receiving Ad5Luc1-OvF vector
expired before tissue harvest at 48 h post-injection and that liver
gene expression was decreased in surviving animals, it is
reasonable to suspect that the increased levels of Ad5Luc1-OvF
in the kidney resulted in the toxicity. In this regard, further
examination of renal tissue inflammation, apoptosis or other
patho-physiology should provide the basis for understanding
this effect observed in some animals.
To our knowledge, this is the first report of a fiber-
pseudotyped Ad vector that simultaneously displays decreased
hepatotropism and a distinct organ tropism in vivo. Furthermore,
this novel redirection of vector biodistribution is directly
attributable to fiber replacement with a non-CAR binding
long-shafted fiber, an outcome seemingly at odds with recent
fiber pseudotyping reports employing short-shafted vectors. In
vitro, Ad5Luc1-OvF displays CAR-independent tropism with a
positive correlation between increased Ad5Luc1-OvF cell-
surface interaction and enhanced gene delivery in CAR-deficient
cells, suggesting the use of as-yet unidentified receptor molecule(s). In addition, this vector may prove useful in murine models of
renal disease.
Materials and methods
Cell lines
The Ad5 DNA-transformed 293 human embryonic cell line
was purchased from Microbix (Toronto, ON, Canada). Human
embryonic rhabdomyosarcoma RD cells, CAR-negative human
U118MG glioma cells, PC-3 and LNCaP human prostate cancer
cells, MCF7 human breast cancer cells, T24 human bladder
cancer cells, Chinese hamster ovary cells (CHO), human
squamous cell carcinoma SCC-4 and SCC-25 cells, FaDu
human pharynx cancer cells, HeLa and SKOV ovarian cancer
cells, LoVo colon cancer cells and OV-3 ovarian cancer cells
were obtained from the American Type Culture Collection
(ATCC) (Manassas, VA). The human ovarian adenocarcinoma
cell lines Hey, SKOV3.ip1 and OV-4 were obtained from Drs.
Judy Wolf, Janet Price (both of M.D. Anderson Cancer Center,
Houston, TX) and Timothy J. Eberlein, (Harvard Medical
School, Boston, MA), respectively. These cell lines were
propagated in 50:50 mixture of Dulbecco's modified Eagle's
medium and Ham's F-12 medium (DMEM/F-12) supplemented
with 10% (v/v) fetal calf serum (FCS), L-glutamine (2 mM),
penicillin (100 units/ml) and streptomycin (100 μg/ml). U118-
hCAR-tailless cells, which express a truncated form of human
CAR comprising the extracellular domain, transmembrane
domain and the first two amino acids from the cytoplasmic
domain (Wang and Bergelson, 1999), have been described
previously (Kim et al., 2003) and were grown in DMEM/F12 as
above except for the addition of 400 μg/ml G418. The ovine
OLE stroma cell line and ovine lung cancer cell line JS8JSRV
were generous gifts from Dr. Massimo Palmarini, University of
Glasgow, UK. All cell lines were cultured at 37 °C in 5% CO2
using culture media recommended by each respective supplier.
FCS was purchased from Gibco-BRL (Grand Island, NY) and
media, and supplements were from Mediatech (Herndon, VA).
Precision-cut human ovarian cancer slices
Human ovarian cancer tissue was obtained taken from
ovarian cancer patients following institutional review board
approval, essentially as described previously (Kirby et al.,
2004). Briefly, excess material was received from the
Department of Obstetrics and Gynecology, the University of
Alabama at Birmingham Hospital. Precision-cut ovarian cancer
slices were prepared using a Krumdiek Tissue Slicer (Alabama
Research and Development, Munford, AL) fitted with a 4 mm
coring device to produce a core biopsy of 4 mm diameter. The
cores were then sliced to 150 μm thickness. Each slice was
transferred into a well of a 24-well plate containing 1 ml
William's Medium E and placed on a rocker. Tumor slices were
maintained at 37 °C in a 5% CO2 environment on a rocker and
allowed to preincubate for 2 h before treatment. Ovarian cancer
slices were infected with 100 and 1000 vp/cell with Ad5Luc1,
Ad5/OAdV7 or no virus. Ovarian cancer slices were harvested
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using a luciferase activity assay system (Promega, Madison,
WI) according to the manufacturer's instructions.
Flow cytometry
Cells grown in T75 flasks were removed by addition of
EDTA in PBS and resuspended in PBS containing 1% bovine
serum albumin (BSA). Cells (2 × 105) were incubated with
3.5 × 109 viral particles of adenovirus, or buffer only, for 1 h at
4 °C in 250 μl PBS–BSA. Cells were then washed twice in 4 ml
cold PBS–BSA and incubated with a 1:500 dilution of poly-
clonal rabbit anti-Ad5 antiserum (Cocalico Biologicals, Reams-
town, PA) at 4 °C in 250 μl PBS–BSA. Cells were washed twice
in 4 ml cold PBS–BSA and incubated in 250 μl of a 1:150
dilution of FITC-labeled goat anti-rabbit IgG secondary anti-
body (Jackson Immunoresearch Labs,West Grove, PA) for 1 h in
PBS–BSA at 4 °C. Flow cytometry analysis was performed at
the UAB FACS Core Facility using FACScan (Beckton
Dickenson, San Jose, CA).
Plasmid construction
To create the chimeric fiber used in this study, we fused the
Ad5 tail domain to the OAdV7 fiber shaft and knob domains. A
1553-bp PCR product containing a 5′ ScaI site, the OAdV7 fiber
shaft and knob domains and a 3′ MunI site was amplified from
plasmid pAK containing the right hand BamHI fragment of the
OAdV7 genome cloned into Bluescribe M13+ BamHI/HincII
sites. The forward primer designated OAdSScaIF was 5′-AGC
GAA GGG TTA GTA CTATCT TTA AAC-3′, and the reverse
primer was designated OAdMunI-R2 5′-TCA TAC AAT TGT
TTA TTA TTG TCT GAA TTG-3′. The underlined bases
indicate insertion of restriction sites, and the stop codon is shown
in bold. Next, a PCR product containing a 5′ PacI site, the Ad5
tail domain and a 3′ ScaI site was amplified from plasmid pNEB.
PK.3.6, a pNEB193-based shuttle vector containing the Ad5
fiber (Krasnykh et al., 1996). The forward primer is designated
NEB36PacIF 5′-ATTACG CCAAGC TTG CAT GCC TGC-3′
and reverse primer NEB36ScaIR 5′-GCAAAGAGAGTACTC
CAG GGG GAC-3′. This PCR product was then digested with
PacI and ScaI and gel-purified. Shuttle vector pNEB.PK.3.6-
OvF was created by a 3-piece ligation of PacI/MunI-digested
pNEB.PK.3.6 and the two digested PCR fragments containing
the Ad5 tail region and the OAdV7 shaft and knob domains.
Direct sequencing confirmed that the coding region for the
chimeric fiber was correct.
Generation of recombinant adenovirus
Recombinant Ad5 genomes containing the chimeric OAdV7
fiber gene were derived by homologous recombination in E. coli
BJ5183 with SwaI-linearized rescue plasmid pVK700 (Belou-
sova et al., 2002) and the fiber-containing PacI–KpnI fragment
of the shuttle vector pNEB.PK.3.6-OvF (described above)
essentially as described (Krasnykh et al., 1998). pVK700 is
derived from pTG3602 (Chartier et al., 1996) but contains analmost complete deletion of the fiber gene and contains a firefly
luciferase reporter gene driven by the cytomegalovirus imme-
diate early promoter in place of the E1 region. Genomic clones
were sequenced and analyzed by PCRprior to transfection of 911
cells. Ad5Luc1 is a replication-defective E1-deleted Ad vector
containing a firefly luciferase reporter gene in the E1 region
driven by the cytomegalovirus immediate early promoter/
enhancer (Krasnykh et al., 2001). All vectors were propagated
on 911 cells and purified by equilibrium centrifugation in CsCl
gradients by a standard protocol. Viral particle (vp) concentration
was determined at 260 nm by the method of Maizel et al. (1968)
by using a conversion factor of 1.1 × 1012 vp/absorbance unit.
Western blot analysis
Aliquots of Ad vectors containing 2.0 × 1010 viral particles
were diluted into Laemmli buffer and incubated at room
temperature or 99 °C for 15 min and loaded onto a 4–20%
gradient SDS-polyacrylamide gel (Bio-Rad, Hercules, CA).
Following electrophoretic protein separation, proteins were
electroblotted onto a PVDF membrane. The primary antibody
(monoclonal 4D2 recognizing the Ad5 fiber tail domain) was
diluted 1:3000 (Lab Vision, Freemont, CA). Immunoblots were
developed by addition of a secondary horseradish-peroxidase-
conjugated anti-mouse immunoglobulin antibody at a 1:3000
dilution (Dako Corporation, Carpentaria, CA) followed by
incubation with 3-3′-diaminobenzene peroxidase substrate
(DAB; Sigma Company, St. Louis, MO).
Recombinant fiber knob proteins
The knob domain of Ad5 was expressed in E. coli with an N-
terminus 6-histidine tag using the pQE81 expression plasmid
(Qiagen, Hilden, Germany). The Ad5 fiber knob domain was
PCR-amplified using primers that amplified the entire fiber knob
domain and the three carboxy-terminal fiber shaft repeats using
the following primers: Ad5 (fwd) 5′-CAAACACGGATCCCCT-
TTTATTATTCTTGGGCAATGTATGA-3′ using plasmid pNEB.
PK.3.6 as the template. The forward primer contains a 2-bp
mutation (in bold) that creates a 5′-end BamHI restriction site
(underlined). The stop codon (TAA) and polyadenylation signal
(AATAAA) are underlined in the reverse primer. The PCR
products containing the Ad5 fiber knob region were digested
with BamHI, gel-purified and ligated into BamHI–SmaI-
digested pQE81. The resulting plasmid pQE81-Ad5 was
sequenced to identify correct clones. The expression plasmid
was introduced into E. coli, and 6-His-containing fiber knob
proteins from bacterial cultures were purified on nickel-
nitrilotriacetic acid (Ni-NTA) agarose columns (Qiagen). The
ability to form trimers was confirmed byWestern blot analysis of
boiled and unboiled purified knob proteins using a mouse penta-
His monoclonal antibody (Qiagen) and a horseradish-peroxi-
dase-conjugated anti-mouse immunoglobulin antibody at a
1:3000 dilution (DAKO Corporation) followed by incubation
with 3-3′-diaminobenzene peroxidase substrate (DAB; Sigma
Company). Concentration of purified knob proteins was
determined by the method of Lowry (Bio-Rad).
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For virus gene transfer experiments using adherent cell
lines, cells were grown in wells of 24-well plates and were
incubated for 1 h at 37 °C with each Ad vector diluted to 100
vp/cell in 500 μl of transduction media containing 2% FCS.
Following the incubation, cells were rinsed in transduction
media and were maintained at 37 °C in an atmosphere of 5%
CO2. Cells were harvested 24 h post-transduction, and gene
transfer was determined using a luciferase activity assay
system (Promega, Madison, WI) according to the manufac-
turer's instructions.
For experiments containing blocking agents, recombinant
fiber knob proteins at 0.5, 5.0 and 50 μg/ml final
concentration were incubated with the cells at 37 °C in
transduction media 15 min before the addition of the virus.
Following the transduction, cells were rinsed with trans-
duction media to remove unbound virus and blocking agent
and were maintained at 37 °C in an atmosphere of 5%
CO2.
Animals
Mice were obtained at 4 to 6 weeks of age and quarantined
at least 1 week before the study. Mice were kept under
pathogen-free conditions according to the American Associ-
ation for Accreditation of Laboratory Animal Care guidelines.
Animal protocols were reviewed and approved by the
Institutional Animal Care and Use Committee of UAB.
Biodistribution
Female C57BL/6 mice (Charles River Laboratories,
Wilmington, MA), aged 6–8 weeks, were injected intrave-
nously through the lateral tail vein with 1 × 1011 vp of
Ad5Luc1, Ad5Luc1-OvF or Ad5-ΔKKTK in 100 μl of PBS.
After 48 h, mice were sacrificed and livers, lungs, spleens,
hearts and kidneys were harvested and representative sections
were frozen in the liquid nitrogen immediately. The frozen
organ samples were homogenized with a Mini Beadbeater
(BioSpec Products, Inc., Bartlesville, OK) in 2 ml micro-tubes
(Research Product International Corp., Mt. Prospect, IL) with
100 μl of 1.0 mm zirconia/silica beads (BioSpec Products,
Inc.) and 1 ml of Cell Culture Lysis Buffer (Promega) then
centrifuged at 14,000 rpm for 2 min. Luciferase activity was
measured as before. Mean background luciferase activity was
subtracted. All luciferase activities were normalized by
protein concentration in the tissue lysates. Protein concentra-
tions were determined using a Bio-Rad DC protein assay kit
(Bio-Rad, Hercules, CA).
Statistics
Data were presented as mean values ± deviation. Statistical
differences among groups were assessed by a two-tailed t test
assuming unequal variance between groups for increased
stringency; P b 0.05 was considered significant.Acknowledgments
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